Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MYOCD antisense RNA 1 (MYOCD-AS1) is a human long non-coding RNA (lncRNA) transcribed antisense to the MYOCD gene, known as a natural antisense transcript (NAT)[4][5][6]. As an antisense lncRNA, MYOCD-AS1 is postulated to regulate the expression and function of the MYOCD (myocardin) gene, a key transcriptional coactivator for smooth muscle and cardiac muscle gene expression, via several mechanisms including transcriptional and post-transcriptional regulation[5]. The exact biological role of MYOCD-AS1 remains incompletely characterized, and no direct therapeutic targeting, disease linkage, or biomarker status has been reported. It is classified as an lncRNA rather than a classical therapeutic target such as a receptor, enzyme, or transporter[4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MYOCD antisense RNA 1 (MYOCD-AS1).